• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.

作者信息

Yim Kein-Leong, Cunningham David

出版信息

Nat Rev Clin Oncol. 2009 Oct;6(10):560-1. doi: 10.1038/nrclinonc.2009.140.

DOI:10.1038/nrclinonc.2009.140
PMID:19786997
Abstract
摘要

相似文献

1
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.化疗：优化用于结直肠癌的伊立替康治疗方案。
Nat Rev Clin Oncol. 2009 Oct;6(10):560-1. doi: 10.1038/nrclinonc.2009.140.
2
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.针对转移性结直肠癌患者，两种不同的含或不含奥沙利铂的一线5-氟尿嘧啶治疗方案。
Ann Oncol. 2009 Feb;20(2):244-50. doi: 10.1093/annonc/mdn638. Epub 2008 Oct 14.
3
What's new in ... colorectal cancer. Meaningful progress in therapy options.结直肠癌领域有哪些新进展？治疗方案取得了重大进展。
JAAPA. 2009 Apr;22(4):51-2. doi: 10.1097/01720610-200904000-00014.
4
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.伊立替康用于转移性结直肠癌：剂量强化及与新药物联合应用，包括生物反应调节剂。
Ann Oncol. 2003;14 Suppl 2:ii17-23. doi: 10.1093/annonc/mdg724.
5
[Recent results of irinotecan therapy in colorectal cancer].[伊立替康治疗结直肠癌的近期结果]
Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17.
6
[Biotherapy in colorectal cancer].[结直肠癌的生物治疗]
J Chir (Paris). 2005 Sep-Oct;142(5):291-6. doi: 10.1016/s0021-7697(05)80932-9.
7
Chemotherapy for metastatic colorectal cancer.转移性结直肠癌的化疗
J Natl Compr Canc Netw. 2005 Jul;3(4):525-9. doi: 10.6004/jnccn.2005.0028.
8
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.在先前未经治疗的转移性结直肠癌患者中，低剂量推注氟尿嘧啶加亚叶酸钙与伊立替康，或持续输注氟尿嘧啶加亚叶酸钙与奥沙利铂的随机对照试验：一项北美协作组试验
J Clin Oncol. 2006 Jul 20;24(21):3347-53. doi: 10.1200/JCO.2006.06.1317.
9
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?化疗：辅助伊立替康在 IV 期 CRC 中有多有效？
Nat Rev Clin Oncol. 2010 Apr;7(4):190-1. doi: 10.1038/nrclinonc.2010.32.
10
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.西妥昔单抗联合XELIRI或XELOX用于转移性结直肠癌的一线治疗。
Clin Colorectal Cancer. 2008 Mar;7(2):110-7. doi: 10.3816/CCC.2008.n.015.

引用本文的文献

1
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.新型 ATM 抑制剂（AZ31）可增强对伊立替康单药治疗耐药的患者来源异种移植瘤的抗肿瘤活性。
Oncotarget. 2017 Dec 5;8(67):110904-110913. doi: 10.18632/oncotarget.22920. eCollection 2017 Dec 19.
2
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.RNA测序揭示了结直肠癌细胞系中伊立替康敏感性/耐药性的决定因素。
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2729-36. eCollection 2014.

本文引用的文献

1
Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.高剂量伊立替康化疗在转移性结直肠癌患者中的当前地位。
J Cancer Res Clin Oncol. 2009 Jun;135(6):749-52. doi: 10.1007/s00432-009-0580-x. Epub 2009 Apr 3.
2
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.在GERCOR OPTIMOX1研究中，FOLFIRI-3（伊立替康D1、D3联合亚叶酸钙-氟尿嘧啶）或其他基于伊立替康的方案在经奥沙利铂预处理的转移性结直肠癌中的疗效。
Ann Oncol. 2009 Jun;20(6):1042-7. doi: 10.1093/annonc/mdn730. Epub 2009 Jan 19.
3
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
EGAPP工作组的建议：UGT1A1基因分型能否降低接受伊立替康治疗的转移性结直肠癌患者的发病率和死亡率？
Genet Med. 2009 Jan;11(1):15-20. doi: 10.1097/GIM.0b013e31818efd9d.
4
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.EPIC：西妥昔单抗联合伊立替康用于氟嘧啶和奥沙利铂治疗失败的转移性结直肠癌患者的III期试验。
J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7.
5
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.晚期预后不良的结直肠癌患者序贯和联合化疗的不同策略（MRC FOCUS）：一项随机对照试验
Lancet. 2007 Jul 14;370(9582):143-152. doi: 10.1016/S0140-6736(07)61087-3.
6
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.一项针对晚期结直肠癌患者在FOLFOX方案治疗后使用FOLFIRI-3（伊立替康双次输注联合LV5FU）的II期研究。
Br J Cancer. 2006 May 8;94(9):1287-92. doi: 10.1038/sj.bjc.6603095.
7
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.OPTIMOX1：一项关于晚期结直肠癌中采用FOLFOX4或FOLFOX7联合奥沙利铂以“停停走走”方式进行治疗的随机研究——一项GERCOR研究
J Clin Oncol. 2006 Jan 20;24(3):394-400. doi: 10.1200/JCO.2005.03.0106.
8
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.伊立替康联合氟尿嘧啶和亚叶酸用于转移性结直肠癌。伊立替康研究组。
N Engl J Med. 2000 Sep 28;343(13):905-14. doi: 10.1056/NEJM200009283431302.
9
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.伊立替康联合氟尿嘧啶与单纯氟尿嘧啶作为转移性结直肠癌一线治疗的比较：一项多中心随机试验。
Lancet. 2000 Mar 25;355(9209):1041-7. doi: 10.1016/s0140-6736(00)02034-1.
10
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.伊立替康联合支持性治疗与单纯支持性治疗用于氟尿嘧啶治疗失败的转移性结直肠癌患者的随机试验
Lancet. 1998 Oct 31;352(9138):1413-8. doi: 10.1016/S0140-6736(98)02309-5.